European Drug Agency Backs New Treatment for Recurring Lung Cancer
Share:
The European Medicines Agency (EMA) has recommended approval for Imdylltra (tarlatamab), a new drug for treating advanced small cell lung cancer in the European Union. The treatment is designed for adult patients whose cancer has returned during or after platinum-based chemotherapy. Small cell lung cancer is an aggressive form of lung cancer that accounts for about 15% of all lung cancer cases and has historically had limited treatment options once it recurs after initial chemotherapy. The EMA's positive recommendation represents a significant development for patients with this difficult-to-treat cancer, as it opens the door for a new therapeutic option in cases where traditional chemotherapy has failed.